Comparison of the virulence of European and North American genotypes of porcine reproductive and respiratory syndrome virus in experimentally infected pigs

Han, Kyu Young; Seo, Hwi Won; Oh, Yuri; Kang, Il Jun; Park, C.; Chae, Chanhee

doi:10.1016/j.tvjl.2012.06.035

Cited by 65 publications

(59 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The challenge strains of type 1 and type 2 PRRSV are virulent, resulting in the most extensive and severe interstitial pneumonia at 7 days postinfection, with lesions resolving between 14 and 21 days postinfection (13,14). Based on previous pathological data, the type 1 PRRSV-based vaccine was evaluated in pigs at 3, 7, 10, and 14 dpc.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, this is the first experimental challenge study to evaluate and compare two commercial type 1 PRRSV-based modified live vaccines against heterologous type 1 and type 2 PRRSV challenge. The lack of cross-protection of the type 1 PRRSV-based modified live vaccine against type 2 PRRSV challenge is clinically significant information because type 2 PRRSV induces more severe respiratory disease than type 1 PRRSV (14,29,30). Nonetheless, the antigenic diversity of the field strains of both genotypes is extreme, and the outcome of vaccination with type 1 PRRSV-based modified live vaccines is difficult to predict.…”

Section: Discussionmentioning

confidence: 99%

“…SNUVR090851 virus was isolated from lung samples from different newly weaned pigs in Chungcheong Province in 2010 (14).…”

mentioning

confidence: 99%

“…The PCR products for the type 1 and type 2 PRRSVs were generated from the type 1 and type 2 challenge PRRSVs by PCR (14). The PCR products were purified with Wizard PCR preps (Promega, Madison, WI).…”

mentioning

confidence: 99%

“…Sections (4 m) were prepared from each tissue and then processed for in situ hybridization to detect in situ viral RNA. In situ hybridization for the detection of type 1 and type 2 PRRSV nucleic acids in lung tissues was performed and analyzed morphometrically, as previously described (14).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs

Kim

Park

Choi

et al. 2015

Clin Vaccine Immunol

View full text Add to dashboard Cite

The objective of the present study was to compare the efficacy of two commercial type 1 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against heterologous type 1 and type 2 PRRSV challenge in growing pigs. Vaccination with a type 1 PRRSV vaccine reduced the level of viremia after type 1 PRRSV challenge but did not reduce the level of viremia after the type 2 PRRSV challenge in pigs. Increased levels of interleukin-10 (IL-10) stimulated by type 2 PRRSV coincided with the low numbers of type 2 PRRSV-specific interferon gamma-secreting cells (IFN-␥-SC) in vaccinated pigs after type 2 PRRSV challenge, whereas low levels of IL-10 stimulated by type 1 PRRSV coincided with high numbers of type 1 PRRSV-specific IFN-␥-SC in vaccinated pigs after type 1 PRRSV challenge. Additionally, vaccination with the type 1 PRRSV vaccine effectively reduced the lung lesions and type 1 PRRSV nucleic acids in type 1 PRRSV-challenged pigs but did not reduce lung lesions and type 2 PRRSV nucleic acids in type 2 PRRSV-challenged pigs. There were no significant differences between two commercial type 1 PRRSV vaccines against type 1 and type 2 PRRSV challenge based on virological results, immunological responses, and pathological outcomes. This study demonstrates that vaccinating pigs with the type 1 PRRSV vaccine provides partial protection against respiratory disease with heterologous type 1 PRRSV challenge but no protection with heterologous type 2 PRRSV challenge. P orcine reproductive and respiratory syndrome (PRRS), caused by PRRS virus (PRRSV), is one of the most economically devastating diseases facing pig production worldwide. The infection of growing pigs with PRRSV causes severe respiratory diseases, leading to impaired growth in postweaned and growing pigs (1). The virus can also give rise to reproductive failure in sows (1). PRRSV is a small, positive-sense, enveloped, single-stranded RNA virus belonging to the family Arteriviridae in the order Nidovirales (2). PRRSV is classified into type 1 (European) and type 2 (North American) genotypes based on the 3=-terminal structural genes or the entire genome (3, 4). Type 1 PRRSV is further divided into three subtypes: a pan-European subtype 1 and East European subtypes 2 and 3, with nucleocapsid protein sizes of 128, 125, and 124 amino acids, respectively (5).In South Korea, type 2 PRRSV was first isolated in 1994 (6). Until 2005, only type 2 PRRSV was detected in Korean swine herds (7,8 Since the first introduction of type 1 PRRSV vaccines, crossprotection is a major clinical issue because of the coexistence of the type 1 and type 2 PRRSVs in swine herds. Previous crossprotection studies have provided inconsistent results (11, 12). The Porcilis PRRS vaccine (MSD Animal Health) provides no protection against heterologous type 2 PRRSV challenge (11), whereas the Amervac PRRS vaccine (Hipra) provides partial protection against heterologous type 2 PRRSV challenge (12). However, a comparison of two commercial type 1 PRRSV-based modified live vaccines a...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…SNUVR090851 virus was isolated from lung samples from different newly weaned pigs in Chungcheong Province in 2010 (14).…”

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs

Kim

Park

Choi

et al. 2015

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

Field efficacy of a novel porcine reproductive and respiratory syndrome modified‐live virus vaccine with an emphasis on growth performance

Ham,

Lee,

Suh

et al. 2024

Veterinary Medicine & Sci

View full text Add to dashboard Cite

BackgroundThis field evaluation was designed to evaluate the efficacy of a new porcine reproductive and respiratory syndrome virus‐2 (PRRSV‐2) modified live virus vaccine at three independent pig farms.MethodsThree farms were selected for this study based on their respiratory disease status caused by PRRSV‐2 infection in post‐weaning and growing pigs. Each farm housed a total of 40, 18‐day‐old pigs that were randomly allocated to one of two treatment groups. Pigs were administered a 1.0 mL dose of the bivalent vaccine intramuscularly at 21 days of age in accordance with the manufacturer's recommendations, whereas unvaccinated pigs were administered a single dose of phosphate buffered saline at the same age.ResultsVaccinated groups were measured and calculated significantly (p < 0.05) higher in body weight and average daily weight gain on all three farms compared with unvaccinated groups. Vaccinated groups elicited PRRS antibodies and PRRSV‐2‐specific interferon‐γ secreting cells, which reduced the amount of PRRSV‐2 genomic copies in the blood and reduced macroscopic and microscopic lung lesions severity when compared with unvaccinated groups.ConclusionsThe field evaluation data demonstrated that a new PRRSV‐2 modified live virus vaccine was efficacious in swine herds suffering from respiratory diseases caused by PRRSV‐2 infection.

show abstract

Comparative evaluation of 4 commercial modified‐live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines against heterologous dual Korean PRRSV‐1 and PRRSV‐2 challenge

Park

Cho

et al. 2020

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Background Four commercial porcine reproductive and respiratory syndrome virus (PRRSV) modified‐live vaccines (MLV) was compared to protect growing pigs against dual challenge of PRRSV‐1 and PRRSV‐2. Methods Two of the vaccines were based on PRRSV‐1, and two on PRRSV‐2. A total of 72 PRRSV‐naïve pigs were divided into six groups (12 pigs/group). Results Two PRRSV‐1 MLV‐vaccinated and two PRRSV‐2 MLV‐vaccinated groups reduced significantly (p < .05) genomic copies of PRRSV‐1 in their sera compared to the unvaccinated challenged group. Two PRRSV‐2 MLV‐vaccinated groups reduced significantly (p < .05) fewer genomic copies of PRRSV‐2 in their sera whereas two PRRSV‐1 MLV‐vaccinated groups were unable to reduce genomic copies of PRRSV‐2 compared to unvaccinated challenged groups. Two PRRSV‐1 MLV‐vaccinated groups induced a stronger PRRSV‐1 specific IFN‐γ‐SC response, while two PRRSV‐2 MLV‐vaccinated groups induced a stronger PRRSV‐2 specific IFN‐γ‐SC response. Two PRRSV‐2 MLV‐vaccinated groups showed significantly (p < .05) lower mean macroscopic and microscopic lung lesion scores compared to two PRRSV‐1 MLV‐vaccinated groups. Conclusions These data demonstrated that two PRRSV‐2 vaccines were efficacious and exhibited similar protection while, two PRRSV‐1 vaccines were largely ineffective against the dual challenge.

show abstract

Comparison of the virulence of European and North American genotypes of porcine reproductive and respiratory syndrome virus in experimentally infected pigs

Cited by 65 publications

References 27 publications

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs

Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs

Field efficacy of a novel porcine reproductive and respiratory syndrome modified‐live virus vaccine with an emphasis on growth performance

Comparative evaluation of 4 commercial modified‐live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines against heterologous dual Korean PRRSV‐1 and PRRSV‐2 challenge

Contact Info

Product

Resources

About